Eyes On Divestments, Revised Guidance Ahead Of Takeda's Q1
As Takeda prepares to report its first full quarter post-Shire next week, eyes will be on further strategic divestments and trends that could lead to a raising of guidance in Q2.
You may also be interested in...
Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.